

## **Preoperative Considerations**

**Consider individual risk factors for every patient** including the need for prophylaxis. Antibiotic choice/dose may need to be modified according to patient factors (e.g. immune suppression, presence of prostheses, allergies, renal function, obesity, malnutrition, diabetes, malignancy, infection at another site, colonisation with multi-drug resistant bacteria and available pathology).

Consider surgical wound classification (clean, clean-contaminated, contaminated, dirty-infected) when determining the need for, or choice of, antibiotic prophylaxis. Refer to Surgical Antimicrobial Prophylaxis Prescribing Guideline for further information.

**Pre-existing infections (known or suspected)** – if present, use appropriate treatment regimen instead of prophylactic regimen for procedure but ensure the treatment regimen has activity against the organism(s) most likely to cause postoperative infection. Adjust the timing of the treatment dose to achieve adequate plasma and tissue concentrations at the time of surgical incision and for the duration of the procedure - seek advice from ID or the AMS team if unsure.

## **Practice Points**

### Timing and administration of antibiotics

Surgical antibiotic prophylaxis must be administered before surgical incision to achieve effective plasma and tissue concentrations at the time of incision. Administration of any antibiotic after skin incision reduces effectiveness.

- > IV cefazolin can be given over 5 minutes and should be administered no more than 60 minutes before skin incision.
- IV vancomycin infusion should be given at a rate of 1g over at least 60 minutes and 1.5g over at least 90 minutes. Vancomycin should be timed to begin 15 to 120 minutes before skin incision. This ensures adequate concentration at the time of incision and allows for any potential infusion-related toxicity to be recognised before induction. The infusion can be completed after skin incision.

#### Dosing in patients with obesity

- > Cefazolin: Consider increased dose of cefazolin (3g) for adult patients weighing more than 120kg.
- > Vancomycin: Consider increased dose of vancomycin (1.5g) for adult patients weighing more than 80kg.

High MRSA risk (defined as history of MRSA colonisation or infection OR frequent stays or a current prolonged stay in hospital with a high prevalence of MRSA OR residence in an area or aged care facility with high prevalence of MRSA OR current residence, or residence in the past 12 months, in a correctional facility):

> Add vancomycin

#### **Repeat dosing**

A single preoperative dose is sufficient for most procedures; however repeat intraoperative doses are advisable:

- > for prolonged surgery (more than 4 hours from the time of first preoperative dose) when a short-acting agent is used (e.g. cefazolin dose should be repeated after 4 hours), OR
- > if major blood loss occurs (e.g. more than 1500 mL in adults), following fluid resuscitation.

When measuring the time to a second intraoperative dose, measure the interval from the time of the first preoperative dose rather than the surgical incision time.

Surgery	Recommended Prophylaxis	High Risk Penicillin / Cephalosporin Allergy*
Breast Procedures		
<b>Uncomplicated clean procedures</b> (diagnostic excisional biopsy, stand-alone sentinel node biopsy, excision of scar tissue, lumpectomy (with or without needle or wire localisation))	Prophylaxis NOT recommended	
<b>Clean-contaminated procedures</b> (reduction mammoplasty, simple mastectomy, wide local excision, axillary lymph node clearance, nipple surgery, all repeat or revision procedures)	cefazolin 2g IV   High risk of MRSA infection:   ADD vancomycin 1g IV infusion (1.5g for patients more than 80kg actual body weight)	<b>vancomycin 1g</b> IV infusion ( <b>1.5g</b> for patients more than 80kg <b>actual body weight</b> )
<b>Complicated clean-contaminated procedures</b> (prosthetic breast reconstruction surgery, prosthetic implant or acellular dermal matrix, autologous breast reconstruction surgery, breast augmentation surgery)	cefazolin 2g IV <u>High risk of MRSA infection:</u> ADD vancomycin 1g IV infusion (1.5g for patients more than 80kg actual body weight)	<b>vancomycin 1g</b> IV infusion ( <b>1.5g</b> for patients more than 80kg <b>actual body weight</b> )
	<b>POST-OPERATIVE:</b> For breast reconstruction or augmentation surgery, a further 2 doses of cefazolin (8 hours apart) can be considered	<b>POST-OPERATIVE:</b> For breast reconstruction or augmentation surgery, a single additional vancomycin dose 12 hours after the first dose can be considered

Recommended Prophylaxis				
Surgery	Recommended Prophylaxis	High Risk Penicillin / Cephalosporin Allergy*		
Other				
<b>Insertion of infusaport or other devices</b> (for procedures using either local & sedation or general anaesthetic)	cefazolin 2g IV <u>High risk of MRSA infection:</u> ADD vancomycin 1g IV infusion (1.5g for patients more than 80kg actual body weight)	vancomycin 1g IV infusion (1.5g for patients more than 80kg actual body weight)		
Clean or clean-contaminated skin procedures (diagnostic excisional biopsy, stand-alone biopsy)	Prophylaxis NOT recommended			

\*High risk penicillin/cephalosporin allergy: History suggestive of high risk (e.g. anaphylaxis, angioedema, bronchospasm, urticaria, DRESS/SJS/TEN)

## Postoperative Care

Except where included above, postoperative antibiotics are NOT indicated unless infection is confirmed or suspected, regardless of the presence of surgical drains. If infection is suspected, consider modification of antibiotic regimen according to clinical condition and microbiology results.

AMS Antimicrobial Stewardship DRESS Drug rash with eosinophilia and systemic symptom	s
	0
ID Infectious Diseases IV Intravenous	
MRSA Methicillin-resistant Staphylococcus aureus SJS / TEN Stevens-Johnson syndrome / toxic epidermal necr	olysis

# References

Antibiotic Expert Group (2019). Therapeutic Guidelines: Antibiotic. Version 16. Melbourne: Therapeutic Guidelines Limited.

Bratzler, D, et al (2013). "Clinical practice guidelines for antimicrobial prophylaxis in surgery." Am J Health Syst Pharm 70 (3): 195-283.

Crawford., C.B. et al (2016) "Surgical site infections in breast surgery: the use of preoperative antibiotics for elective, nonreconstructive procedures". Int J of Breast Cancer 1-7. http://dx.doi.org/10.1155/2016/1645192

Hai, Y., Chong, W., Lazar, M. (2020) "Extended prophylactic antibiotics for mastectomy with immediate breast reconstruction: A meta-analysis" PRS Global Open: 1-8 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015589/pdf/gox-8-e2613.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015589/pdf/gox-8-e2613.pdf</a>

Gallagher, M. Jones, DJ., Bell-Syer, S. (2019) Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Library <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005360.pub5/full">https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005360.pub5/full</a>

Anderson, DJ., Sexton, DJ. (2021). "Antimicrobial prophylaxis for pevention of surgical site infection in adults". In: Harris, A (ed). UptoDate. Waltham, MA. [www.uptodate.com]. Accessed February 2021.

Endorsed by South Australian expert Advisory Group on Antibiotic Resistance (SAAGAR). Last reviewed and amended December 2021.

SAAGAR has endeavoured to ensure that the information in this publication is accurate at the time of writing; however, it makes no representation or warranty to this effect. SAAGAR disclaims all liability for any claims, losses, damages, costs and expenses suffered or incurred as a result of reliance on this publication.

